elderli
may
suffer
inappropri
medic
due
decreas
vision
memori
loss
impair
cognit
low
complianc
unsupervis
care
hospit
histori
previou
antibacteri
therapi
physic
declin
mechan
ventil
risk
factor
lrti
popul
elderli
infect
usual
manifest
atyp
symptom
lethargi
loss
appetit
mental
disord
thu
inexperienc
caregiv
tend
ignor
symptom
lead
miss
diagnosi
inappropri
use
antibiot
increas
disabl
mortal
elderli
one
major
caus
grow
lrti
burden
increas
antimicrobi
resist
streptococcu
pneumonia
pneumonia
clamydia
pneumonia
staphylococcu
aureu
bacteri
pathogen
remain
common
caus
lrti
resist
pathogen
macrolid
fluoroquinolon
continu
increas
alarm
rate
worldwid
gisk
et
al
woodhead
et
al
exampl
us
isol
pneumonia
test
macrolideresist
increas
report
highlevel
macrolid
resist
across
us
jone
et
al
also
case
europ
ale
et
al
asid
pneumonia
atyp
lrtiscaus
pathogen
mycoplasma
pneumonia
also
produc
increas
antibiot
resist
asch
et
al
elderli
due
longterm
use
broadspectrum
antibiot
immunosuppress
invas
oper
increas
antibiot
resist
ultim
lead
excess
hospit
treatment
failur
financi
burden
addit
physician
familiar
physiolog
characterist
elderli
precaut
common
medic
result
inappropri
use
antibiot
combin
therapi
quinolon
warfarin
increas
risk
bleed
elderli
patient
lead
qt
prolong
interact
macrolid
statin
may
lead
rhabdomyolysi
acut
kidney
injuri
combin
therapi
macrolid
fluoroquinolon
sulfonylurea
may
caus
sever
hypoglycemia
elderli
fluoroquinolon
macrolid
sulfonamid
nitrofuran
may
caus
damag
central
nervou
system
cn
fungal
infect
may
associ
longterm
use
antibiot
addit
antibiot
may
affect
accuraci
diagnost
test
due
high
preval
lrti
elderli
hospit
outpati
set
tabl
epidemiolog
differ
atyp
clinic
manifest
agerel
variat
pharmacokinet
pharmacodynam
make
lrti
manag
elderli
challeng
standard
treatment
earli
stage
lrti
critic
reduc
death
disabl
present
accord
global
burden
diseas
gbd
studi
jame
et
al
burden
lrti
peopl
older
year
old
still
increas
mani
region
troeger
et
al
alter
respiratori
structur
caus
age
song
chang
impair
organ
function
poulos
raju
chang
drugsuscept
alldr
et
al
chronic
low
grade
inflamm
boyd
orihuela
togeth
lead
increas
suscept
lrti
meanwhil
exist
comorbid
age
drug
resist
preval
mortal
lrti
elderli
much
higher
age
group
thu
huge
demand
develop
novel
pharmacotherapi
elderli
antibiot
seem
cornerston
lrti
manag
katzan
et
al
et
al
choi
et
al
base
exist
data
phase
clinic
trial
latest
antibiot
purpos
articl
recommend
promis
antibiot
treatment
lrti
elderli
meanwhil
briefli
review
current
medic
respiratori
communic
diseas
elderli
aim
obtain
better
manag
lrti
clinic
practic
comprehens
review
research
statu
medic
lrti
elderli
antibiot
current
advanc
stage
develop
phase
trial
beyond
systemat
retriev
follow
sourc
includ
pubm
medlin
ovidsp
embas
ovidsp
octob
juli
collect
clinic
trial
manual
screen
trial
thirtyseven
phase
trial
eighteen
phase
trial
three
phase
trial
respect
final
elabor
advantag
limit
applic
novel
antibiot
clinic
practic
base
trial
random
control
trial
rct
includ
studi
share
follow
characterist
trial
includ
patient
year
age
met
least
three
symptom
cough
purul
sputum
dyspnea
pleurisi
least
two
abnorm
vital
sign
least
one
laboratori
test
result
clinic
sign
associ
lrti
radiolog
confirm
pneumonia
trial
classifi
risk
class
pneumonia
sever
index
psi
rang
ii
v
trial
includ
regist
clinicaltrialsgov
assess
efficaci
safeti
certain
antibiot
popul
analysi
end
point
assess
consid
analysi
popul
includ
intentiontotreat
itt
popul
includ
subject
underw
random
clinic
evalu
ce
popul
defin
subject
surviv
resolut
improv
symptom
infect
antibacteri
therapi
requir
microbiolog
intentiontotreat
mitt
popul
defin
subject
itt
popul
caus
pathogen
pathogen
identifi
baselin
cultur
blood
respiratori
specimen
use
cultureindepend
method
clinic
perprotocol
popul
defin
subject
itt
popul
qualifi
infect
defin
trial
entri
criteria
receiv
trial
agent
receiv
antibacteri
agent
sign
within
trial
could
confound
interpret
trial
result
undergon
assess
result
protocol
defin
window
microbiolog
perprotocol
popul
includ
patient
clinic
perprotocol
popul
mitt
popul
regard
end
point
firstli
primari
efficaci
end
point
evalu
earli
clinic
respons
ecr
defin
surviv
improv
one
level
rel
baselin
two
symptom
pneumonia
worsen
one
level
symptom
pneumonia
without
receipt
rescu
antibacteri
therapi
gener
ecr
assess
h
first
dose
trial
drug
itt
popul
secondari
end
point
investigatorassess
clinic
respons
posttreat
evalu
day
last
dose
clinic
respons
defin
resolut
improv
sign
symptom
extent
antibacteri
therapi
unnecessari
time
also
evalu
advers
reaction
antibiot
includ
mild
advers
event
seriou
advers
event
sae
defin
advers
event
emerg
treatment
initi
treatment
discontinu
mortal
arm
also
analyz
safeti
certain
agent
recent
year
new
fluoroquinolon
agent
tabl
delafloxacin
nemonoxacin
zabofloxacin
identifi
effect
exist
fluoroquinoloneresist
pathogen
new
fluoroquinolon
agent
target
topoisomeras
iv
dna
gyras
stronger
affin
result
inhibit
bacteri
dna
replic
kollef
betthaus
reduc
mutant
select
toxic
side
effect
result
superior
potent
activ
common
commun
acquir
pneumonia
cap
pathogen
pfaller
et
al
delafloxacin
effect
gramposit
bacteria
includ
methicillin
sensit
staphylococcu
aureu
mssa
methicillin
resist
staphylococcu
aureu
mrsa
moraxella
catarrhali
catarrhali
pneumonia
nemonoxacin
effect
gramposit
bacteria
includ
multidrugresist
pneumonia
mrsa
ertapenemnonsuscept
enterobacteriacea
legionella
chlamydophila
mycoplasma
antibacteri
activ
zabofloxacin
mssa
mrsa
similar
gemifloxacin
time
stronger
moxifloxacin
ciprofloxacin
park
et
al
rct
phase
conduct
cap
patient
receiv
nemonoxacin
mg
levofloxacin
mg
oral
daili
day
total
patient
year
old
random
treat
nemonoxacin
levofloxacin
clinic
cure
rate
test
cure
toc
visit
nemonoxacin
levofloxacin
mitt
popul
microbiolog
success
rate
nemonoxacin
levofloxacin
mitt
popul
nemonoxacin
effect
safe
levofloxacin
treatment
adult
cap
patient
term
clinic
cure
rate
microbiolog
success
rate
safeti
profil
yuan
et
al
phrase
noninferior
trial
old
patient
account
major
particip
repeatedli
confirm
safeti
efficaci
nemonoxacin
treatment
cap
van
rensburg
et
al
chang
et
al
novel
mechan
action
nemonoxacin
target
topoisomeras
iv
dna
gyras
inhibit
dna
synthesi
requir
bacteri
growth
li
et
al
frequenc
interact
creatinin
clearanc
mlmin
dosag
levofloxacin
need
adjust
nemonoxacin
induc
inhibit
isozym
cao
et
al
dosag
adjust
requir
elderli
impair
renal
hepat
function
side
effect
unlik
commerci
avail
fluoroquinolon
agent
moxifloxacin
levofloxacin
nemonoxacin
exhibit
evid
phototox
system
activ
allerg
reaction
signific
hepatotox
sever
cn
toxic
liang
et
al
zhang
et
al
dose
regimen
system
review
metaanalysi
rct
demonstr
compar
mg
levofloxacin
nemonoxacin
mg
mg
safe
cardiac
conduct
measur
ecg
qtc
prolong
chang
et
al
addit
singledos
escal
nemonoxacin
mg
studi
show
clinic
signific
chang
correct
qt
healthi
chines
volunt
luke
et
al
mg
dosag
significantli
higher
risk
advers
effect
mg
dosag
nemonoxacin
mg
regimen
may
adequ
treatment
cap
roychoudhuri
et
al
oral
dosag
nemonoxacin
mg
daili
mg
twice
daili
levofloxacin
make
nemonoxacin
potenti
therapi
elderli
lrti
multicent
noninferior
rct
phase
evalu
safeti
efficaci
oral
zabofloxacin
mg
daili
day
vs
oral
moxifloxacin
mg
daili
day
treat
acut
bacteri
exacerb
chronic
obstruct
pulmonari
diseas
copd
particip
moder
acut
bacteri
exacerb
copd
select
subgroup
patient
without
chronic
bronchiti
suffer
lrti
antibacteri
efficaci
zabofloxacin
moxifloxacin
therapi
observ
cure
rate
respect
statist
differ
acut
ae
seriou
ae
detect
two
arm
rhee
et
al
novel
mechan
action
zabofloxacin
inhibit
dna
gyras
topoisomeras
iv
thu
inhibit
bacteri
dna
replic
park
et
al
zabofloxacin
show
potent
vitro
activ
pneumonia
isol
caus
invas
pneumococc
diseas
even
levofloxacinresist
strain
kwon
et
al
side
effect
advers
effect
includ
nausea
hypotens
somnol
increas
blood
phosphokinas
common
minor
subsid
spontan
meanwhil
qt
prolong
detect
kocsi
et
al
dose
regimen
dose
regimen
rel
simpl
requir
one
dose
per
day
rct
phase
comparison
delafloxacin
moxifloxacin
treatment
adult
cap
complet
present
result
trial
still
pend
base
situat
recommend
delafloxacin
firstlin
agent
lrti
elderli
omadacyclin
tabl
novel
oncedaili
aminomethylcyclin
antibiot
becam
second
tetracyclin
antibiot
approv
fda
omadacyclin
antimicrobi
activ
gramposit
gramneg
anaerob
atyp
pathogen
dougherti
et
al
omadacyclin
higher
coverag
mrsa
penicillin
multidrugresist
pneumonia
vancomycinresist
enterococci
vre
omadacyclin
also
good
activ
h
influenza
catarrhali
pneumonia
l
pneumophila
enterobacteriacea
ureaplasma
spp
bacillu
anthraci
yersinia
pesti
clostridium
difficil
pfaller
et
al
phase
trial
efficaci
safeti
omacyclin
cap
patient
success
complet
total
cap
patient
psi
randomli
enrol
two
group
equal
size
patient
two
group
took
intraven
omadacyclin
moxifloxacin
first
three
day
transit
oral
omadacyclin
moxifloxacin
respect
overal
patient
itt
popul
older
year
old
psi
risk
class
iii
iv
popul
studi
show
signific
differ
two
arm
term
ecr
day
clinic
respons
incid
ae
patient
die
older
year
old
eight
omadacyclin
group
four
moxifloxacin
group
death
might
caus
progress
underli
pneumonia
respiratori
compromis
hap
cardiac
vascular
event
cancer
neither
group
clinic
relev
chang
baselin
vital
sign
laboratori
test
ecg
find
research
conclud
death
group
relat
underli
diseas
rather
two
antibiot
summari
efficaci
omadacyclin
treatment
cap
inferior
moxifloxacin
stet
et
al
novel
mechan
action
chemic
structur
omadacyclin
contain
uniqu
alkylaminomethyl
side
chain
posit
tetracyclin
frequenc
interact
omadacyclin
mild
drug
interact
favor
safeti
profil
vitro
research
found
omadacyclin
affect
cytochrom
common
ae
omadacyclin
gastrointestin
symptom
clinic
signific
differ
omadacyclin
pharmacokinet
observ
base
age
need
elderli
impair
hepat
function
adjust
dose
omadacyclin
dose
regimen
dose
regimen
rel
simplist
one
dose
need
per
day
regimen
greatli
reduc
likelihood
impairedcognit
patient
take
repeat
medicin
forget
take
medicin
solithromycin
tabl
novel
gener
macrolid
first
fluoroketolid
complet
phase
clinic
trial
show
activ
pathogen
associ
lrti
includ
macrolidepenicillinresist
isol
pneumonia
solithromycin
influenc
format
function
ribosom
subunit
caus
frameshift
mutat
translat
still
et
al
due
lack
cladinos
moieti
induc
erm
b
mediat
resist
et
al
less
suscept
mef
mediat
efflux
macrolid
result
increas
ribosom
bind
greater
intrins
activ
darpo
et
al
one
trial
compar
antibacteri
efficaci
safeti
oral
solithromycin
treatment
cap
central
noninferior
rct
studi
patient
randomli
assign
receiv
either
oral
solithromycin
moxifloxacin
result
show
particip
ecr
solithromycin
group
compar
moxifloxacin
group
show
equival
efficaci
solithromycin
primari
endpoint
subject
year
age
histori
asthma
copd
higher
success
rate
ecr
short
term
followup
without
copd
addit
ecr
rate
higher
group
may
relat
immunomodulatori
effect
solithromycin
among
group
barrera
et
al
anoth
phase
trial
efficaci
safeti
intravenoustoor
solithromycin
assess
intravenoustoor
moxifloxacin
treatment
cap
trial
ecr
itt
popul
age
year
old
older
year
old
show
noninferior
solithromycin
primari
endpoint
respect
incid
rate
seriou
ae
compar
group
signific
file
et
al
solithromycin
mani
advantag
provid
elderli
popul
novel
mechan
action
solithromycin
demonstr
increas
ribosom
bind
comparison
macrolid
meanwhil
first
fluoroketolid
fluorin
contribut
tighter
bind
increas
activ
potenti
resist
appear
low
darpo
et
al
frequenc
interact
due
inhibit
isoenzym
pathway
frequent
drugdrug
interact
like
macrolid
erythromycin
clarithromycin
side
effect
mild
rel
low
frequenc
howev
concern
sever
hepat
toxic
requir
evalu
hook
et
al
dose
regimen
solithromycin
also
simpl
dose
regimen
oncedaili
dose
treatment
cap
elderli
poor
vision
memori
loss
cognit
impair
low
selfadher
prefer
choic
moreov
solithromycin
avail
oral
intraven
iv
formul
highli
potent
effect
bacteriostat
properti
erad
rate
pharmacodynam
pd
perspect
ceftarolin
tabl
approv
fda
european
medicin
agenc
ema
treatment
cap
broadspectrum
activ
especi
potent
antibacteri
activ
gramposit
bacteria
make
ceftarolin
ideal
antibiot
treatment
cap
efficaci
safeti
ceftarolin
establish
two
mileston
studi
focu
focu
focu
enrol
cap
patient
age
year
old
experiment
group
treat
intraven
ceftarolin
mg
h
day
control
group
treat
ceftriaxon
clarithromycin
focu
recruit
cap
patient
criteria
almost
half
patient
across
group
age
year
old
arm
took
intervent
focu
clarithromycin
use
adjuv
therapi
focu
focu
ceftarolin
ceftriaxon
well
toler
similar
rate
ae
seriou
ae
death
discontinu
file
et
al
low
et
al
anoth
publish
rct
includ
asian
cap
port
risk
class
patient
meet
criteria
focu
experiment
group
use
exactli
intervent
focu
control
group
use
doubl
dosag
ceftriaxon
result
show
ceftarolin
superior
ceftriaxon
clinic
evalu
ce
mitt
popul
signific
differ
safeti
two
agent
zhong
et
al
phase
multicent
studi
propos
specif
evalu
safeti
efficaci
ceftarolin
treatment
cap
patient
year
age
studi
withdrawn
unknown
reason
studi
safeti
efficaci
ceftarolin
cap
recruit
yield
result
novel
mechan
action
compar
penicillin
cephalosporin
antibiot
ceftarolin
higher
affin
penicillinbind
protein
pbp
destroy
cell
wall
format
quickli
effect
justo
et
al
broadspectrum
activ
especi
potent
antibacteri
activ
resist
gramposit
bacteria
make
ideal
drug
treatment
cap
frequenc
interact
side
effect
side
effect
solithromycin
mild
frequenc
rel
low
elderli
patient
moder
impair
renal
function
ceftarolin
requir
dose
adjust
dose
regimen
regimen
simpl
intraven
infus
twice
day
suffici
ceftobiprol
tabl
good
activ
gramposit
pathogen
speciesdepend
activ
gramneg
pathogen
curcio
two
larg
scale
vitro
studi
farrel
et
al
hodil
et
al
ceftobiprol
show
ceftobiprol
strong
activ
mssa
suscept
respect
mrsa
suscept
respect
pneumonia
suscept
respect
major
enterobacteriacea
suscept
respect
potenc
ceftobiprol
p
aeruginosa
suscept
respect
similar
ceftazidim
kresken
et
al
elderli
peopl
longterm
care
facil
ltcf
agent
necessari
coverag
rare
pathogen
ceftobiprol
good
antibacteri
activ
common
pathogen
ltcf
enterobacteriacea
p
aeruginosa
nowaday
ceftobiprol
approv
sever
european
countri
treatment
cap
hap
exclud
vap
scheeren
safeti
efficaci
ceftobiprol
demonstr
two
phase
trial
patient
cap
hap
exclud
vap
first
studi
demonstr
intraven
ceftobiprol
equival
efficaci
ceftriaxon
without
linezolid
detail
clinic
cure
rate
cap
patient
vs
clinic
evalu
popul
ci
vs
itt
popul
ci
pneumoniaspecif
mortal
within
first
day
low
group
addit
common
seriou
ae
ceftobiprol
arm
mild
compar
ceftriaxon
arm
nicholson
et
al
second
rct
demonstr
ceftobiprol
noninferior
ceftazidim
without
linezolid
worth
note
cure
rate
vap
patient
vs
vs
suggest
ceftobiprol
unsuit
treatment
vap
awad
et
al
retrospect
studi
rct
evalu
earli
clinic
improv
subgroup
highrisk
patient
subgroup
highrisk
patient
cap
patient
year
old
cap
patient
copd
hap
patient
baselin
comorbid
particular
signific
result
observ
seem
favor
ceftobiprol
compar
pooley
et
al
novel
mechan
action
ceftobiprol
strong
affin
pbp
respons
antibacteri
activ
staphylococci
pneumococci
falco
et
al
pneumonia
patient
comorbid
ceftobiprol
strong
bactericid
effect
quickli
improv
clinic
symptom
ensur
better
prognosi
frequenc
interact
ceftobiprol
elimin
expect
significantli
affect
minor
elimin
rout
dose
adjust
necessari
subject
renal
impair
pfaller
et
al
side
effect
comorbid
patient
older
year
old
incid
advers
event
caus
ceftobiprol
similar
nonhighrisk
patient
suggest
ceftobiprol
safe
effect
highrisk
group
addit
ceftobiprol
less
like
caus
antibioticrel
intestin
flora
disord
horn
et
al
lefamulin
tabl
potent
semisynthet
antibacteri
agent
belong
novel
class
known
pleuromutilin
lefamulin
vitro
antibacteri
profil
includ
import
bacteri
pathogen
caus
lrti
antibacteri
spectrum
compris
pneumonia
h
influenza
catarrhali
atyp
respiratori
pathogen
mrsa
streptococci
enterococcu
faecium
wait
et
al
veve
wagner
moreov
demonstr
crossresist
studi
lefamulin
remain
activ
clinic
isol
resist
follow
antibiot
macrolid
lincosamid
streptogramin
b
oxazolidinon
tetracyclin
quinolon
trimethoprimsulfametoxazol
mupirocin
vancomycin
mend
et
al
paukner
et
al
phase
clinic
trial
evalu
safeti
efficaci
lefamulin
treatment
cap
complet
particip
cap
random
receiv
lefamulin
mg
iv
everi
h
moxifloxacin
mg
daili
six
dose
patient
could
switch
oral
administr
prespecifi
improv
criteria
met
mrsa
suspect
linezolid
ad
moxifloxacin
patient
age
year
old
account
lefamulin
moxifloxacin
group
respect
age
lefamulin
noninferior
moxifloxacin
ecr
investig
assess
clinic
respons
iacr
lefamulin
low
incid
drug
resist
minim
crossresist
type
antibiot
make
new
monotherapi
elderli
cap
file
et
al
oral
dosag
form
lefamulin
investig
leap
primari
endpoint
similar
leap
major
differ
studi
design
includ
use
oral
drug
without
addit
linezolid
moxifloxacin
group
leap
result
expect
avail
second
half
leap
patient
year
age
account
lefamulin
moxifloxacin
group
respect
age
lefamulin
noninferior
moxifloxacin
ecr
iacr
novel
mechan
action
inhibit
protein
synthesi
bind
bacteri
ribosom
subunit
veve
wagner
ensur
lefamulin
low
incid
drug
resist
minim
crossresist
type
antibiot
make
new
monotherapi
elderli
cap
frequenc
interact
lefamulin
littl
inhibitori
effect
howev
worth
note
high
protein
bind
capac
could
lead
drug
interact
wait
et
al
side
effect
lefamulin
mild
side
effect
highli
effect
common
cap
pathogen
mend
et
al
pristinamycin
tabl
streptococcaltyp
antibiot
produc
streptomyc
faecali
inhibit
protein
synthesi
bind
bacteri
ribosom
subunit
nespoul
et
al
pristinamycin
strong
antibacteri
activ
mrsa
mssa
h
influenza
pneumonia
cooper
et
al
addit
pristinamycin
synergist
antibacteri
effect
vancomycin
reid
et
al
phase
studi
intend
evalu
safeti
efficaci
pristinamycin
treatment
mild
cap
expect
complet
may
noteworthi
trial
exclud
patient
moder
sever
cap
may
limit
generaliz
addit
pristinamycin
oral
formul
unlik
ever
role
treat
old
patient
sever
cap
recommend
pristinamycin
promis
treatment
cap
iclaprim
tabl
broadspectrum
diaminopyrimidin
antibiot
inhibit
dihydrofol
reductas
cross
react
human
enzym
laue
et
al
iclaprim
develop
treat
seriou
respiratori
infect
hospit
acquir
pneumonia
hap
attribut
multidrugresist
gramposit
pathogen
cystic
fibrosi
caus
aureu
huang
et
al
huang
et
al
one
phase
clinic
trial
focus
explor
iclaprim
efficaci
hap
caus
gramposit
bacteria
trial
complet
therefor
iclaprim
recommend
routin
treatment
elderli
hap
telavancin
tabl
novel
semisynthet
lipoglycopeptid
activ
multidrug
resist
mdr
staphylococci
enterococci
streptococci
telavancin
approv
fda
hap
ventilatorassoci
bacteri
pneumonia
vabp
telavancin
high
antibacteri
efficaci
aureu
mgl
epidermidi
mgl
mssa
mrsa
visa
mgl
streptococcu
vanb
protein
enterococcu
mgl
poor
effect
vrsa
mgl
vana
protein
enterococcu
mgl
hassoun
et
al
two
rct
name
attain
enrol
hap
patient
random
receiv
telavancin
mgkg
qd
vancomycin
g
result
studi
indic
telavancin
wors
vancomycin
term
clinic
cure
rate
toc
visit
attain
studi
subgroup
analysi
also
show
telavancin
better
effect
simpl
aureu
infect
vancomycin
better
effect
mix
infect
gramposit
gramneg
bacteria
mrsa
telavancin
vancomycin
similar
effect
similar
rate
ae
telavancin
caus
higher
proport
peopl
elev
serum
creatinin
level
vancomycin
vs
barrier
summari
ecg
monitor
necessari
elderli
patient
histori
qt
prolong
time
patient
use
telavancin
monitor
coagul
paramet
dose
al
jalali
zeitling
novel
mechan
action
telavancin
dual
antibacteri
mechan
action
inhibit
bacteri
cell
wall
synthesi
interf
crosslink
transpeptid
polymer
rubinstein
et
al
meanwhil
telavancin
caus
cell
death
increas
membran
permeabl
result
leakag
intracellular
potassium
atp
frequenc
interact
telavancin
mild
inhibitori
effect
da
et
al
thu
also
use
elderli
hepat
dysfunct
howev
worth
note
high
protein
bind
capac
could
lead
drug
drug
interact
al
jalali
zeitling
side
effect
telavancin
mild
side
effect
high
potenc
common
cap
pathogen
dose
regimen
singledosag
twodosag
regimen
greatli
improv
complianc
old
patient
addit
compar
vancomycin
telavancin
advantag
potent
antibacteri
activ
mrsa
visa
even
vrsa
well
long
halflif
good
antibacteri
activ
fill
gap
vancomycin
resist
barrier
base
detail
moder
recommend
telavancin
promis
antibiot
lrti
elderli
tedizolid
tabl
approv
fda
treatment
acut
bacteri
skin
skin
structur
infect
absssi
tedizolid
one
prospect
agent
spectrum
activ
mrsa
vre
common
pathogen
nosocomi
pneumonia
flanagan
et
al
tedizolid
share
mani
structur
featur
linezolid
increas
antimicrobi
potenc
linezolid
mani
studi
confirm
antibacteri
potenti
tedizolid
linezolidsuscept
linezolidresist
gramposit
pathogen
much
higher
linezolid
brown
traczewski
date
phase
trial
assess
efficaci
tedizolid
treatment
hap
complet
document
shortterm
anim
clinic
studi
report
neuropathi
thrombocytopenia
associ
tedizolid
safeti
tedizolid
longterm
administr
remain
seen
random
phase
studi
safeti
efficaci
tedizolid
comparison
linezolid
patient
hap
vap
current
ongo
primari
endpoint
determin
noninferior
ni
allcaus
mortal
acm
within
day
random
intraven
tedizolid
phosphat
compar
intraven
linezolid
itt
analysi
set
ventil
particip
gramposit
nosocomi
pneumonia
result
expect
complet
februari
research
announc
result
trial
novel
mechan
action
addit
interact
conserv
region
ribosom
subunit
dring
substitu
tedizolid
contribut
strong
antibacteri
potenti
level
tedizolid
penetr
epitheli
line
fluid
elf
alveolar
macrophag
much
higher
freedrug
exposur
plasma
housman
et
al
side
effect
presenc
linezolid
resist
hematolog
side
effect
lodis
et
al
tedizolid
better
choic
frequenc
interact
elderli
degre
hepat
renal
dysfunct
dose
adjust
warrant
elderli
achiev
therapeut
goal
dose
regimen
addit
better
bioavail
foodindepend
efficaci
simpl
dose
regimen
support
daili
administr
make
tedizolid
popular
clinician
retrospect
studi
patient
diabet
reveal
high
correl
preval
infect
fast
blood
glucos
fbg
elderli
rayfield
et
al
addit
among
patient
admit
hospit
lrti
admiss
rate
patient
diabet
winterbau
et
al
kornum
et
al
peleg
et
al
casqueiro
et
al
risk
complic
peleg
et
al
mortal
fine
et
al
kornum
et
al
significantli
higher
patient
without
diabet
doubl
hit
age
immun
system
host
defens
may
impair
diabet
togeth
increas
risk
bacteri
mycobacteri
fungal
viral
infect
furthermor
respiratori
dysfunct
microangiopathi
togeth
lead
higher
morbid
mortal
diabet
elderli
kornum
et
al
antimicrobi
pharmacotherapi
elderli
diabet
age
group
mandel
et
al
data
suggest
elderli
patient
receiv
aminoglycosid
wors
outcom
gleason
et
al
medic
regimen
individu
take
account
patient
recent
antibiot
medic
histori
comorbid
suspect
aspir
suspect
pseudomona
infect
allergi
pneumonia
patient
diabet
patient
recent
use
antibiot
take
advanc
macrolid
respiratori
fluoroquinolon
contrast
patient
use
antibiot
recent
choos
fluoroquinolon
advanc
macrolid
chronic
use
inhal
glucocorticoid
elderli
associ
increas
risk
diabet
physician
awar
order
select
patient
benefit
outweigh
risk
battaglia
et
al
time
also
import
manag
blood
glucos
level
infect
patient
meanwhil
diabet
patient
usual
vari
degre
impair
renal
function
antibiot
nephrotox
avoid
pulmonari
fungal
infect
occur
old
patient
normal
impair
immun
function
morbid
mortal
fungal
pneumonia
among
elderli
increas
significantli
recent
year
reason
increas
patient
malign
tumor
well
organ
transplant
autoimmun
diseas
result
increas
patient
immunocompromis
lead
increas
incid
fungal
pneumonia
limper
et
al
chen
et
al
candida
pneumonia
rare
fact
isol
candida
respiratori
secret
clinic
signific
case
chen
et
al
immunecompet
pulmonari
cryptococcosi
host
fluconazol
itraconazol
recommend
immunocompromis
host
recommend
treat
amphotericin
b
combin
flucytosin
follow
fluconazol
itraconazol
li
et
al
patient
normal
immun
function
patient
pulmonari
aspergillosi
recommend
inhal
glucocorticoid
bronchodil
leukotrien
receptor
antagonist
den
et
al
immunocompromis
patient
invas
pulmonari
aspergillosi
advis
take
oral
fluconazol
itraconazol
intraven
amphotericin
b
blanchard
et
al
elderli
patient
immunodefici
intraven
caspofungin
micafungin
recommend
follow
oral
fluconazol
itraconazol
bao
et
al
meanwhil
oral
administr
posaconazol
begin
treatment
anoth
choic
clark
et
al
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
singlestrand
envelop
positivesens
rna
virus
age
underli
diseas
pivot
independ
predictor
miscellan
advers
outcom
sar
chan
et
al
sar
case
mainli
seen
young
healthi
individu
patient
year
old
highest
mortal
wherea
half
case
merscov
infect
occur
individu
age
chan
et
al
assiri
et
al
differ
treatment
option
elderli
age
group
current
commonli
prescrib
antivir
regimen
ribavirin
ifn
lopinavirritonavir
morgenstern
et
al
altawfiq
et
al
omrani
et
al
ribavirin
nucleosid
analogu
broadspectrum
antivir
activ
inhibit
viral
rna
synthesi
mrna
cap
von
grotthuss
et
al
efficaci
ribavirin
alon
combin
treatment
sar
inconsist
controversi
chu
et
al
leong
et
al
canada
announc
ban
ribavirin
treatment
sar
due
report
side
effect
inadequ
efficaci
chiou
et
al
lopinavir
ritonavir
proteas
inhibitor
may
inhibit
proteas
mer
improv
clinic
outcom
compar
ribavirin
alon
sar
patient
chan
et
al
stockman
et
al
still
commerci
vaccin
avail
merscov
hart
et
al
multipl
vaccin
candid
target
protein
respons
viral
entri
develop
includ
subunit
vaccin
wang
et
al
tai
et
al
recombin
vector
vaccin
kim
et
al
gilbert
warimw
dna
vaccin
alamri
et
al
chi
et
al
agent
mycophenol
acid
mpa
prevent
replic
viral
rna
show
strong
inhibit
activ
merscov
vitro
studi
hart
et
al
addit
passiv
immunotherapi
use
human
plasma
also
appli
treatment
sar
mer
arabi
et
al
mairjenkin
et
al
gener
corticosteroid
wide
use
along
ribavirin
sar
outbreak
lee
et
al
varieti
agent
includ
antivir
peptid
monoclon
antibodi
cellular
viral
proteas
inhibitor
may
promis
agent
vitro
andor
anim
model
ohnuma
et
al
tao
et
al
agraw
et
al
zumla
et
al
efficaci
patient
sar
mer
need
clinic
valid
vitro
experi
ifn
product
effect
inhibit
sarscov
morgenstern
et
al
chan
et
al
meanwhil
although
specif
antivir
merscov
sarscov
develop
medic
repurpos
potenti
loperamid
de
wild
et
al
chloroquin
keyaert
et
al
cyclophilin
stamn
et
al
kinas
inhibitor
dyall
et
al
may
present
addit
therapeut
futur
coronavirus
influenzarel
death
gradual
increas
increas
age
yu
et
al
adult
year
old
account
approxim
influenzarel
hospit
casey
et
al
nicol
data
central
south
america
cheng
et
al
european
centr
diseas
prevent
control
ecdc
surveil
commun
unit
africa
cohen
et
al
southeast
asia
wong
et
al
park
et
al
ang
et
al
consist
report
higher
morbid
mortal
old
adult
due
doubt
potenc
influenza
vaccin
vaccin
rate
influenza
vaccin
among
elderli
low
schmid
et
al
addit
insuffici
suppli
vaccin
vaccin
hesit
also
contribut
inadequ
vaccin
elderli
standarddos
sd
influenza
vaccin
studi
among
elderli
estim
benefit
prevent
hospit
mortal
due
pneumonia
nichol
et
al
nichol
et
al
jansen
et
al
meanwhil
highdos
hd
trival
influenza
vaccin
tiv
effect
sd
influenza
vaccin
prevent
probabl
influenza
infect
effect
sd
influenza
vaccin
prevent
influenza
hospit
admiss
izurieta
et
al
anoth
retrospect
cohort
us
veteran
found
group
signific
reduct
hospit
influenza
pneumonia
associ
hd
tiv
inject
richardson
et
al
accord
observ
studi
rct
hd
tiv
wong
et
al
park
et
al
influenza
vaccin
appear
efficaci
clinic
influenza
ie
ili
serolog
confirm
influenza
adult
older
year
old
govaert
et
al
engler
et
al
taylor
et
al
van
buynder
et
al
darvishian
et
al
domnich
et
al
shay
et
al
diagnos
influenza
neuraminidas
inhibitor
nai
includ
oseltamivir
dobson
et
al
zanamivir
heneghan
et
al
peramivir
effect
influenza
influenza
b
virus
review
number
newli
develop
agent
systemat
purpos
weigh
rel
advantag
limit
util
elderli
popul
accord
key
advantag
classifi
antibiot
recommend
moder
recommend
recommend
exampl
telavancin
better
bioavail
foodindepend
efficaci
simpl
dose
regimen
support
daili
administr
make
potenti
therapi
elderli
lrti
nemonoxacin
trial
medicin
enrol
patient
age
age
group
separ
subgroup
test
safeti
efficaci
certain
antibiot
alon
consid
elderli
account
major
particip
still
recommend
nemonoxacin
firstlin
medic
lrti
elderli
accord
key
criteria
formul
contrast
zabofloxaxin
littl
potenti
treatment
lrti
elderli
although
potenti
therapi
copd
patient
moderatesever
exacerb
zabofloxacin
ineffect
common
noncommun
acquir
pathogen
aeruginosa
baumannii
elderli
patient
longterm
care
center
overhospit
patient
underli
diseas
cystic
fibrosi
note
zabofloxacin
may
applic
han
et
al
addit
safeti
efficaci
intraven
formul
zabofloxacin
still
unclear
moreov
zabofloxacin
approv
food
drug
administr
fda
cap
treatment
telavancin
novel
semisynthet
lipoglycopeptid
activ
multidrug
resist
mdr
staphylococci
enterococci
streptococci
telavancin
better
bioavail
foodindepend
efficaci
simpl
dose
regimen
support
daili
administr
make
potenti
therapi
old
peopl
lrti
omadacyclin
novel
oncedaili
aminomethylcyclin
antibiot
becam
second
tetracyclin
antibiot
approv
fda
despit
obviou
advantag
omadacyclin
enough
attent
given
drawback
cardiac
electrophysiolog
name
chang
heart
rate
hr
qt
interv
dura
sousa
member
macrolid
solithromycin
littl
potenti
treatment
lrti
elderli
base
fact
solithromycin
inhibitor
caution
use
coadminist
solithromycin
agent
demonstr
interact
preced
macrolid
solithromycin
appear
affect
plasma
concentr
digoxin
warfarin
probabl
due
interact
pglycoprotein
lead
bradydysrhythmia
increas
bleed
risk
elderli
still
et
al
sleep
disord
relat
medic
benzodiazepin
commonli
use
elderli
medic
mainli
metabol
induc
side
effect
attenu
therapeut
effect
kasper
resing
therefor
combin
two
categori
agent
avoid
unavoid
dose
benzodiazepin
reduc
ceftarolin
approv
fda
european
medicin
agenc
ema
treatment
cap
ceftarolin
recommend
intraven
format
hospit
set
elderli
cap
patient
creatinin
clearanc
mlmin
qt
prolong
histori
port
risk
class
first
lack
oral
formul
ceftarolin
limit
properti
use
hospit
set
secondli
ceftarolin
weak
antibacteri
activ
efaecium
vre
esbl
p
aeruginosa
kiang
et
al
common
pathogen
found
hap
patient
comorbid
longterm
nurs
home
frequent
treat
antibiot
addit
although
ae
mostli
mild
focu
ceftarolin
patient
ceftriaxon
patient
develop
qtcb
prolong
ms
elong
ms
compar
baselin
anoth
cephalosporin
ceftobiprol
suitabl
patient
suspect
pneumonia
caus
mrsa
enterobacteriacea
p
aeruginosa
especi
patient
live
nurs
home
long
time
data
elderli
popul
requir
recommend
ceftobiprol
iv
limit
daili
activ
elderli
old
peopl
malnutrit
impair
cognit
function
risk
sarcopenia
delirium
pressur
ulcer
sputum
may
increas
survey
onethird
clinic
trial
center
found
larg
portion
data
center
unreli
unverifi
abba
et
al
jean
et
al
thu
fda
request
inform
recommend
addit
clinic
studi
ceftobiprol
approv
csssi
pneumonia
summar
key
advantag
lefamulin
treatment
lrti
opinion
lefamulin
recommend
promis
agent
lrti
elderli
attent
must
paid
interact
medicin
azol
antifung
paukner
et
al
midazolam
file
et
al
time
beyond
take
h
intraven
use
lefamulin
less
limit
activ
elderli
patient
increas
possibl
convuls
insuffici
evid
support
tedizolid
ideal
antibiot
therapi
lrti
elderli
present
tedizolid
still
fdaemaapprov
antibiot
treatment
lrti
bring
hope
patient
suffer
liver
kidney
organ
failur
especi
lrti
associ
linezolidresist
gramposit
pathogen
although
phase
trial
tedizolid
hap
yet
yield
result
tedizolid
bring
hope
old
patient
suffer
renal
hepat
failur
especi
linezolidresist
gramposit
pathogen
pneumonia
flanagan
et
al
despit
noteworthi
decreas
number
death
due
lrti
remain
urgent
need
make
effort
reduc
burden
diseas
elderli
especi
physic
declin
mechan
ventil
immunosuppress
frailti
dementia
comorbid
although
pharmacotherapi
guidelin
specif
old
patient
lrti
pharmacist
clinician
need
weigh
variou
advantag
limit
base
typic
challeng
face
elderli
choos
optim
pharmacotherapi
yl
bd
conceiv
design
project
yl
yz
wz
contribut
significantli
submit
work
wrote
first
draft
yl
xl
fh
revis
manuscript
author
read
approv
final
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
